Structural aspects of chemical modifications in the MHC-restricted immunopeptidome; Implications for immune recognition
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Significant advances in mass-spectroscopy (MS) have made it possible to investigate the cellular immunopeptidome, a large collection of MHC-associated epitopes presented on the surface of healthy, stressed and infected cells. These approaches have hitherto allowed the unambiguous identification of large cohorts of epitope sequences that are restricted to specific MHC class I and II molecules, enhancing our understanding of the quantities, qualities and origins of these peptide populations. Most importantly these analyses provide essential information about the immunopeptidome in responses to pathogens, autoimmunity and cancer, and will hopefully allow for future tailored individual therapies. Protein post-translational modifications (PTM) play a key role in cellular functions, and are essential for both maintaining cellular homeostasis and increasing the diversity of the proteome. A significant proportion of proteins is post-translationally modified, and thus a deeper understanding of the importance of PTM epitopes in immunopeptidomes is essential for a thorough and stringent understanding of these peptide populations. The aim of the present review is to provide a structural insight into the impact of PTM peptides on stability of MHC/peptide complexes, and how these may alter/modulate immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycosylation and the Immune System
Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A., & Dwek, R. A. (2001) · Science · doi:10.1126/science.291.5512.2370 · Cited by 1,588 · cited 2×
“Indeed, almost all of the key proteins that are involved in the cellular immune system are glycoproteins (Rudd et al., 2001).”
BackgroundMechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846 · cited 1×
“MHC-IIrestricted cancer- or other disease-associated epitopes (Linnemann et al., 2015; Alspach et al., 2019), enhances significantly our capacity to design novel and/or improve already existing CD8 and CD4 T cell-based therapies through specific modifications (Chen et al.”
BackgroundPresent yourself! by MHC class I and MHC class II molecules
Rock, K. L., Reits, E., & Neefjes, J. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.08.010 · Cited by 814 · cited 1×
“Thus, although we provide here below a short description of MHC-I and MHC-II antigen processing and presentation, we refer the readers to other more comprehensive and detailed reviews of these pathways (Rock et al., 2016; Dersh et al., 2021).”
BackgroundBassani-Sternberg, M., Bräunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13404 · Cited by 693
Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.015 · Cited by 538 · cited 1×
“cancer immunotherapy or treatment of autoimmune diseases (Bassani-Sternberg et al., 2016; Wells et al., 2020).”
BackgroundSaveanu, L., Carroll, O., Lindo, V., Del Val, M., Lopez, D., Lepelletier, Y., Greer, F., Schomburg, L., Fruci, D., Niedermann, G., et al. (2005) · Nature Immunology · doi:10.1038/ni1208 · Cited by 481
Scally, S. W., Petersen, J., Law, S. C., Dudek, N. L., Nel, H. J., Loh, K. L., Wijeyewickrema, L. C., Eckle, S. B. G., van Heemst, J., Pike, R. N., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131241 · Cited by 429 · cited 12×
“Structural studies have demonstrated that citrullination of an arginine residue at p4 can result in the creation of a neo-selfantigen since this PTMmakes it possible for the modified epitope to bind to HLA-DRB1*0401 or HLA-DRB1*0101, while the wildtype peptide cannot (Figure 4A) (Ting et al., 2018).”
BackgroundInfluentialOncogenic Roles of the PI3K/AKT/mTOR axis
Aoki, M., & Fujishita, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_6 · Cited by 355
Wang, F., Wang, K., Xu, W., Zhao, S., Ye, D., Wang, Y., Xu, Y., Zhou, L., Chu, Y., Zhang, C., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.065 · Cited by 340
Research works printed but not linked: 153
- Achour, 2002, A structural basis for LCMV immune evasion: Subversion of H-2D(b) and H-2K(b) presentation of gp33 revealed by comparative crystal structure.Analyses, Immunity, 17, 757, 10.1016/s1074-7613(02)00478-8 · DOI
- Alpízar, 2017, A molecular basis for the presentation of phosphorylated peptides by HLA-B antigens, Mol. Cell. Proteomics, 16, 181, 10.1074/mcp.m116.063800 · DOI · Paper page
- Andersen, 1999, Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL, J. Immunol., 163, 3812, 10.4049/jimmunol.163.7.3812 · DOI · Paper page
- Ayyoub, 1999, A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells, J. Biol. Chem., 274, 10227, 10.1074/jbc.274.15.10227 · DOI
- Bagdonaite, 2018, Global aspects of viral glycosylation, Glycobiology, 28, 443, 10.1093/glycob/cwy021 · DOI · Paper page
- Baker, 2000, Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: Implications for TCR signaling, Immunity, 13, 475, 10.1016/s1074-7613(00)00047-9 · doi:10.1016/s1074-7613(00)00047-9
- Bassani-Sternberg, 2015, Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation, Mol. Cell. Proteomics, 14, 658, 10.1074/mcp.m114.042812 · DOI · Paper page
- Beltrami, 2008, Citrullination-dependent differential presentation of a self-peptide by HLA-B27 subtypes, J. Biol. Chem., 283, 27189, 10.1074/jbc.m802818200 · DOI
- Bennun, 2013, Integration of the transcriptome and glycome for identification of glycan cell signatures, PLoS Comput. Biol., 9, e1002813, 10.1371/journal.pcbi.1002813 · DOI · Paper page
- Bergseng, 2015, Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires, Immunogenetics, 67, 73, 10.1007/s00251-014-0819-9 · DOI · Paper page
- Blees, 2017, Structure of the human MHC-I peptide-loading complex, Nature, 551, 525, 10.1038/nature24627 · DOI · Paper page
- Blum, 2013, Pathways of antigen processing, Annu. Rev. Immunol., 31, 443, 10.1146/annurev-immunol-032712-095910 · DOI · Paper page
- Bourdetsky, 2014, The nature and extent of contributions by defective ribosome products to the HLA peptidome, Proc. Natl. Acad. Sci. U. S. A., 111, E1591, 10.1073/pnas.1321902111 · DOI
- Brewerton, 1973, Ankylosing spondylitis and HL-A 27, Lancet, 1, 904, 10.1016/s0140-6736(73)91360-3 · DOI · Paper page
- Bruning, 2018, Impairment of angiogenesis by fatty acid synthase inhibition involves mTOR malonylation, Cell. Metab., 28, 866, 10.1016/j.cmet.2018.07.019 · DOI · Paper page
- Cable, 2021, Frontiers in cancer immunotherapy-a symposium report, Ann. N. Y. Acad. Sci., 1489, 30, 10.1111/nyas.14526 · DOI
- Campbell, 2018, Metabolic signaling to the nucleus in cancer, Mol. Cell., 71, 398, 10.1016/j.molcel.2018.07.015 · DOI · Paper page
- Caron, 2015, Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry, Mol. Cell. Proteomics, 14, 3105, 10.1074/mcp.o115.052431 · DOI · Paper page
- Celie, 2009, UV-induced ligand exchange in MHC class I protein crystals, J. Am. Chem. Soc., 131, 12298, 10.1021/ja9037559 · DOI
- Chambers, 2007, Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination, Cancer Res., 67, 8450, 10.1158/0008-5472.can-07-1092 · DOI
- Chang, 2016, Human oncogenic herpesvirus and post-translational modifications - phosphorylation and SUMOylation, Front. Microbiol., 7, 962, 10.3389/fmicb.2016.00962 · doi:10.3389/fmicb.2016.00962
- Chen, 2017, Role of HLA-B27 in the pathogenesis of ankylosing spondylitis, Mol. Med. Rep., 15, 1943, 10.3892/mmr.2017.6248 · DOI · Paper page
- Chen, 2005, Structural and kinetic basis for heightened immunogenicity of T cell vaccines, J. Exp. Med., 201, 1243, 10.1084/jem.20042323 · DOI · Paper page
- Chen, 2018, Post-translational modification-based regulation of HIV replication, Front. Microbiol., 9, 2131, 10.3389/fmicb.2018.02131 · DOI
- Chessman, 2008, Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity, Immunity, 28, 822, 10.1016/j.immuni.2008.04.020 · DOI · Paper page
- Compañón, 2019, Structure-based design of potent tumor-associated antigens: Modulation of peptide presentation by single-atom O/S or O/Se substitutions at the glycosidic linkage, J. Am. Chem. Soc., 141, 4063, 10.1021/jacs.8b13503 · DOI
- Cook, 2018, Citrullinated α-enolase is an effective target for anti-cancer immunity, Oncoimmunology, 7, e1390642, 10.1080/2162402x.2017.1390642 · DOI · Paper page
- Depontieu, 2009, Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy, Proc. Natl. Acad. Sci. U. S. A., 106, 12073, 10.1073/pnas.0903852106 · DOI · Paper page
- Dersh, 2021, A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion, Nat. Rev. Immunol., 21, 116, 10.1038/s41577-020-0390-6 · DOI · Paper page
- Ding, 1999, Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical, Immunity, 11, 45, 10.1016/s1074-7613(00)80080-1 · DOI · Paper page
- Diskin, 2021, Modification of proteins by metabolites in immunity, Immunity, 54, 19, 10.1016/j.immuni.2020.09.014 · DOI · Paper page
- Dudler, 1995, Carbohydrate-dependent, HLA class II-restricted, human T cell response to the bee venom allergen phospholipase A2 in allergic patients, Eur. J. Immunol., 25, 538, 10.1002/eji.1830250235 · DOI · Paper page
- Duraj, 2021, Metabolic therapy and bioenergetic analysis: The missing piece of the puzzle, Mol. Metab., 54, 101389, 10.1016/j.molmet.2021.101389 · DOI
- Duru, 2020, Tuning antiviral CD8 T-cell response via proline-altered peptide ligand vaccination, PLoS Pathog., 16, e1008244, 10.1371/journal.ppat.1008244 · DOI · Paper page
- Ene, 2020, Posttranslational modifications pattern in clear cell renal cell carcinoma, Metabolites, 11, 10, 10.3390/metabo11010010 · DOI
- Faridi, 2018, A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands, Sci. Immunol., 3, eaar3947, 10.1126/sciimmunol.aar3947 · DOI · Paper page
- Fremont, 1992, Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb, Science, 257, 919, 10.1126/science.1323877 · DOI · Paper page
- Fugmann, 2017, The MHC class II immunopeptidome of lymph nodes in health and in chemically induced colitis, J. I., 198, 1357, 10.4049/jimmunol.1601157 · DOI
- Gerstner, 2016, Functional and structural characterization of a novel HLA-drb1*04:01-restricted α-enolase T cell epitope in rheumatoid arthritis, Front. Immunol., 7, 494, 10.3389/fimmu.2016.00494 · DOI · Paper page
- Ghanem, 2021, The pentose phosphate pathway in cancer: Regulation and therapeutic opportunities, Chemotherapy, 66, 179, 10.1159/000519784 · DOI
- Glithero, 1999, Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity, Immunity, 10, 63, 10.1016/s1074-7613(00)80007-2 · DOI
- Gómez-Nuñez, 2008, Non-natural and photo-reactive amino acids as biochemical probes of immune function, PLoS One, 3, e3938, 10.1371/journal.pone.0003938 · DOI
- Granados, 2015, The nature of self for T cells-a systems-level perspective, Curr. Opin. Immunol., 34, 1, 10.1016/j.coi.2014.10.012 · DOI
- Guichard, 1996, Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2, J. Med. Chem., 39, 2030, 10.1021/jm9509511 · DOI · Paper page
- Hafstrand, 2017, Crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity, PLoS One, 12, e0189584, 10.1371/journal.pone.0189584 · DOI
- Hafstrand, 2016, The MHC class I cancer-associated neoepitope Trh4 linked with impaired peptide processing induces a unique noncanonical TCR conformer, J. I., 196, 2327, 10.4049/jimmunol.1502249 · doi:10.4049/jimmunol.1502249
- Hafstrand, 2018, The immunogenicity of a proline-substituted altered peptide ligand toward the cancer-associated TEIPP neoepitope Trh4 is unrelated to complex stability, J. I., 200, 2860, 10.4049/jimmunol.1700228 · DOI
- Hanada, 2004, Immune recognition of a human renal cancer antigen through post-translational protein splicing, Nature, 427, 252, 10.1038/nature02240 · DOI · Paper page
- Hardy, 2008, Conversion of tyrosine to the inflammation-associated analog 3'-nitrotyrosine at either TCR- or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells, J. Immunol., 180, 5956, 10.4049/jimmunol.180.9.5956 · DOI · Paper page
- Harriff, 2017, HLA-E presents glycopeptides from the Mycobacterium tuberculosis protein MPT32 to human CD8+ T cells, Sci. Rep., 7, 4622, 10.1038/s41598-017-04894-0 · DOI
- Hastie, 2016, Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV, Nat. Struct. Mol. Biol., 23, 513, 10.1038/nsmb.3210 · DOI
- Herzog, 2005, Activated antigen-presenting cells select and present chemically modified peptides recognized by unique CD4 T cells, Proc. Natl. Acad. Sci. U. S. A., 102, 7928, 10.1073/pnas.0502255102 · DOI · Paper page
- Hoppes, 2014, Altered peptide ligands revisited: Vaccine design through chemically modified HLA-A2-restricted T cell epitopes, J. I., 193, 4803, 10.4049/jimmunol.1400800 · DOI · Paper page
- Hudrisier, 2001, Molecular and functional dissection of the H-2Db-restricted subdominant cytotoxic T-cell response to lymphocytic choriomeningitis virus, J. Virol., 75, 2468, 10.1128/jvi.75.5.2468-2471.2001 · doi:10.1128/jvi.75.5.2468-2471.2001
- Hudrisier, 1999, Genetically encoded and post-translationally modified forms of a major histocompatibility complex class I-restricted antigen bearing a glycosylation motif are independently processed and co-presented to cytotoxic T lymphocytes, J. Biol. Chem., 274, 36274, 10.1074/jbc.274.51.36274 · DOI
- Hülsmeyer, 2004, Dual, HLA-B27 subtype-dependent conformation of a self-peptide, J. Exp. Med., 199, 271, 10.1084/jem.20031690 · DOI
- Illing, 2018, HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome, Nat. Commun., 9, 4693, 10.1038/s41467-018-07109-w · DOI
- Irvine, 2020, Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases, Glycobiology, 30, 241, 10.1093/glycob/cwaa018 · DOI
- Istrail, 2004, Comparative immunopeptidomics of humans and their pathogens, Proc. Natl. Acad. Sci. U. S. A., 101, 13268, 10.1073/pnas.0404740101 · DOI · Paper page
- James, 2010, HLA-DR1001 presents "altered-self" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets, Arthritis Rheum., 62, 2909, 10.1002/art.27594 · DOI
- Jarrold, 2019, PRMTs and arginine methylation: Cancer's best-kept secret?, Trends Mol. Med., 25, 993, 10.1016/j.molmed.2019.05.007 · DOI · Paper page
- Jennewein, 2017, The immunoregulatory roles of antibody glycosylation, Trends Immunol., 38, 358, 10.1016/j.it.2017.02.004 · DOI · Paper page
- Jiang, 2021, Wilms tumor gent 1 (WT1)-specific adoptive immunotherapy in hematologic diseases, Int. Immunopharmacol., 94, 107504, 10.1016/j.intimp.2021.107504 · DOI
- Jones, 2006, Synthesis and biological evaluation of two chemically modified peptide epitopes for the class I MHC protein HLA-B*2705, Org. Biomol. Chem., 4, 3769, 10.1039/b611170j · doi:10.1039/b611170j
- Kanaseki, 2006, ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum, Immunity, 25, 795, 10.1016/j.immuni.2006.09.012 · DOI
- Kastrup, 2001, MHC-restricted T cell responses against posttranslationally modified peptide antigens, Adv. Immunol., 78, 267, 10.1016/s0065-2776(01)78006-6 · DOI
- Khan, 2013, Polymorphism of HLA-B27: 105 subtypes currently known, Curr. Rheumatol. Rep., 15, 362, 10.1007/s11926-013-0362-y · DOI
- Kiessling, 2016, TAP-ing into TIEPPs for cancer immunotherapy, J. Clin. Invest., 126, 480, 10.1172/jci86119 · doi:10.1172/jci86119
- Klein, 1986, Seeds of time: Fifty years ago peter A. Gorer discovered the H-2 complex, Immunogenetics, 24, 331, 10.1007/bf00377947 · doi:10.1007/bf00377947
- Kloetzel, 2001, Antigen processing by the proteasome, Nat. Rev. Mol. Cell. Biol., 2, 179, 10.1038/35056572 · DOI · Paper page
- Kloetzel, 2022, Neo-splicetopes in tumor therapy: A lost case?, Front. Immunol., 13, 849863, 10.3389/fimmu.2022.849863 · DOI
- Knierman, 2020, The human leukocyte antigen class II immunopeptidome of the SARS-CoV-2 spike glycoprotein, Cell. Rep., 33, 108454, 10.1016/j.celrep.2020.108454 · DOI · Paper page
- Krebs, 1998, Binding of rationally designed non-natural peptides to the human leukocyte antigen HLA-B*2705, J. Pept. Sci., 4, 378, 10.1002/(sici)1099-1387(199809)4:6<378::aid-psc157>3.0.co;2-b · doi:10.1002/(sici)1099-1387(199809)4:6<378::aid-psc157>3.0.co;2-b
- Kumar, 2020, Role of host-mediated post-translational modifications (PTMs) in RNA virus pathogenesis, Int. J. Mol. Sci., 22, 323, 10.3390/ijms22010323 · DOI · Paper page
- Lampen, 2018, Breadth and dynamics of HLA-A2– and HLA-B7–restricted CD8+ T cell responses against nonstructural viral proteins in acute human tick-borne encephalitis virus infection, Immunohorizons, 2, 172, 10.4049/immunohorizons.1800029 · DOI
- Lande, 2021, Complementary effects of carbamylated and citrullinated LL37 in autoimmunity and inflammation in systemic lupus erythematosus, Int. J. Mol. Sci., 22, 1650, 10.3390/ijms22041650 · DOI
- Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213 · DOI · Paper page
- Leeming, 2011, Post-translational modifications of the extracellular matrix are key events in cancer progression: Opportunities for biochemical marker development, Biomarkers, 16, 193, 10.3109/1354750x.2011.557440 · DOI
- Liepe, 2016, A large fraction of HLA class I ligands are proteasome-generated spliced peptides, Science, 354, 354, 10.1126/science.aaf4384 · DOI · Paper page
- Lim, 2021, The shared susceptibility epitope of HLA-DR4 binds citrullinated self-antigens and the TCR, Sci. Immunol., 6, eabe0896, 10.1126/sciimmunol.abe0896 · DOI
- Lindqvist, 2009, Structural basis for substrate recognition and specificity in aklavinone-11-hydroxylase from rhodomycin biosynthesis, J. Mol. Biol., 393, 966, 10.1016/j.jmb.2009.09.003 · doi:10.1016/j.jmb.2009.09.003
- Linnemann, 2015, High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma, Nat. Med., 21, 81, 10.1038/nm.3773 · DOI · Paper page
- Liu, 2021, IgG N-glycans, Adv. Clin. Chem., 105, 1, 10.1016/bs.acc.2021.02.001 · DOI
- Liu, 2019, A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response, Biomater. Sci., 7, 5516, 10.1039/c9bm01183h · DOI
- Madhurantakam, 2012, Inflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complex, PLoS One, 7, e32805, 10.1371/journal.pone.0032805 · DOI
- Malaker, Identification and characterization of complex glycosylated peptides presented by the MHC class II processing pathway in melanoma, J. Proteome Res., 16, 228, 10.1021/acs.jproteome.6b00496 · DOI · Paper page
- Malaker, Identification of glycopeptides as posttranslationally modified neoantigens in leukemia, Cancer Immunol. Res., 5, 376, 10.1158/2326-6066.cir-16-0280 · DOI · Paper page
- Mann, 2003, Proteomic analysis of post-translational modifications, Nat. Biotechnol., 21, 255, 10.1038/nbt0303-255 · DOI · Paper page
- Marijt, TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers, Mol. Immunol., 113, 43, 10.1016/j.molimm.2018.03.029 · DOI
- Marijt, TEIPP peptides: Exploration of unTAPped cancer antigens, Oncoimmunology, 8, 1599639, 10.1080/2162402x.2019.1599639 · DOI
- Marino, 2015, Extended O-GlcNAc on HLA class-I-bound peptides, J. Am. Chem. Soc., 137, 10922, 10.1021/jacs.5b06586 · DOI · Paper page
- Mei, 2020, Immunopeptidomic analysis reveals that deamidated HLA-bound peptides arise predominantly from deglycosylated precursors, Mol. Cell. Proteomics, 19, 1236, 10.1074/mcp.ra119.001846 · DOI · Paper page
- Mereiter, 2019, Glycosylation in the era of cancer-targeted therapy: Where are we heading?, Cancer Cell., 36, 6, 10.1016/j.ccell.2019.06.006 · DOI · Paper page
- Michaëlsson, 1994, T cell recognition of carbohydrates on type II collagen, J. Exp. Med., 180, 745, 10.1084/jem.180.2.745 · DOI · Paper page
- Mishto, 2019, An in silico—In vitro pipeline identifying an HLA-A*02:01+ KRAS G12V+ spliced epitope candidate for a broad tumor-immune response in cancer patients, Front. Immunol., 10, 2572, 10.3389/fimmu.2019.02572 · DOI · Paper page
- Mizukoshi, 2011, Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma, Hepatology, 53, 1206, 10.1002/hep.24149 · DOI · Paper page
- Mohammed, 2017, The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status, Oncotarget, 8, 54160, 10.18632/oncotarget.16952 · DOI · Paper page
- Mommen, 2014, Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD), Proc. Natl. Acad. Sci. U. S. A., 111, 4507, 10.1073/pnas.1321458111 · DOI · Paper page
- Mommen, 2016, Sampling from the proteome to the human leukocyte antigen-DR (HLA-DR) ligandome proceeds via high specificity, Mol. Cell. Proteomics, 15, 1412, 10.1074/mcp.m115.055780 · DOI
- Mondal, 2021, Chemical biology of protein citrullination by the protein A arginine deiminases, Curr. Opin. Chem. Biol., 63, 19, 10.1016/j.cbpa.2021.01.010 · DOI
- Morita, 2016, Lipopeptides: A novel antigen repertoire presented by major histocompatibility complex class I molecules, Immunology, 149, 139, 10.1111/imm.12646 · DOI
- Newton, 2018, Protein kinase C: Perfectly balanced, Crit. Rev. Biochem. Mol. Biol., 53, 208, 10.1080/10409238.2018.1442408 · DOI · Paper page
- Nguyen, 2021, Can glycosylation mask the detection of MHC expressing p53 peptides by T cell receptors?, Biomolecules, 11, 1056, 10.3390/biom11071056 · DOI
- Nuriel, 2011, Protein nitrotryptophan: Formation, significance and identification, J. Proteomics, 74, 2300, 10.1016/j.jprot.2011.05.032 · DOI · Paper page
- Olsen, 2006, Global, in vivo, and site-specific phosphorylation dynamics in signaling networks, Cell., 127, 635, 10.1016/j.cell.2006.09.026 · DOI · Paper page
- Olvera, 2020, Does antigen glycosylation impact the HIV-specific T cell immunity?, Front. Immunol., 11, 573928, 10.3389/fimmu.2020.573928 · DOI
- Parker, 2021, Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells, Cell. Rep., 35, 109179, 10.1016/j.celrep.2021.109179 · DOI · Paper page
- Pearson, 2016, MHC class I-associated peptides derive from selective regions of the human genome, J. Clin. Invest., 126, 4690, 10.1172/jci88590 · DOI · Paper page
- Peixoto, 2019, Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks, Front. Oncol., 9, 380, 10.3389/fonc.2019.00380 · DOI · Paper page
- Petersen, Post-translationally modified T cell epitopes: Immune recognition and immunotherapy, J. Mol. Med., 87, 1045, 10.1007/s00109-009-0526-4 · DOI
- Petersen, Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes, Proc. Natl. Acad. Sci. U. S. A., 106, 2776, 10.1073/pnas.0812901106 · DOI · Paper page
- Pieper, 2018, Memory T cells specific to citrullinated α-enolase are enriched in the rheumatic joint, J. Autoimmun., 92, 47, 10.1016/j.jaut.2018.04.004 · DOI
- Powell, 1992, Peptide stability in drug development: A comparison of peptide reactivity in different biological media, J. Pharm. Sci., 81, 731, 10.1002/jps.2600810802 · DOI
- Proulx, 2020, Post-translational modifications inducing proteasomal degradation to counter HIV-1 infection, Virus Res., 289, 198142, 10.1016/j.virusres.2020.198142 · DOI
- Prus, 2019, Analysis and interpretation of protein post-translational modification site stoichiometry, Trends biochem. Sci., 44, 943, 10.1016/j.tibs.2019.06.003 · DOI · Paper page
- Rane, 2019, P21 activated kinase signaling in cancer, Semin. Cancer Biol., 54, 40, 10.1016/j.semcancer.2018.01.006 · DOI · Paper page
- Revathidevi, 2019, Akt in cancer: Mediator and more, Semin. Cancer Biol., 59, 80, 10.1016/j.semcancer.2019.06.002 · DOI · Paper page
- Richman, 1979, Cancer immunotherapy, Can. Med. Assoc. J., 120, 322
- Rosado, 2021, ADP-ribosylation in evasion, promotion and exacerbation of immune responses, Immunology, 164, 15, 10.1111/imm.13332 · DOI
- Rosendahl Huber, 2016, Chemical modification of influenza CD8+ T-cell epitopes enhances their immunogenicity regardless of immunodominance, PLoS One, 11, e0156462, 10.1371/journal.pone.0156462 · DOI
- Santos, 2017, Protein posttranslational modifications: Roles in aging and age-related disease, Oxid. Med. Cell. Longev., 2017, 5716409, 10.1155/2017/5716409 · DOI · Paper page
- Schuster, 2018, A tissue-based draft map of the murine MHC class I immunopeptidome, Sci. Data, 5, 180157, 10.1038/sdata.2018.157 · DOI
- Seo, 2004, Post-translational modifications and their biological functions: Proteomic analysis and systematic approaches, BMB Rep., 37, 35, 10.5483/bmbrep.2004.37.1.035 · DOI · Paper page
- Shao, 2018, The SysteMHC atlas project, Nucleic Acids Res., 46, D1237, 10.1093/nar/gkx664 · DOI · Paper page
- Sidney, 2018, Low HLA binding of diabetes-associated CD8+ T-cell epitopes is increased by post translational modifications, BMC Immunol., 19, 12, 10.1186/s12865-018-0250-3 · DOI · Paper page
- Singh, 2017, Phosphorylation: Implications in cancer, Protein J., 36, 1, 10.1007/s10930-017-9696-z · DOI · Paper page
- Skipper, 1996, An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins, J. Exp. Med., 183, 527, 10.1084/jem.183.2.527 · DOI · Paper page
- Sofron, 2016, High-resolution analysis of the murine MHC class II immunopeptidome, Eur. J. Immunol., 46, 319, 10.1002/eji.201545930 · DOI · Paper page
- Song, 2021, Post-translational modification control of viral DNA sensors and innate immune signaling, Adv. Virus Res., 109, 163, 10.1016/bs.aivir.2021.03.001 · DOI
- Speir, 1999, Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL, Immunity, 10, 51, 10.1016/s1074-7613(00)80006-0 · DOI
- Stern, 2016, The melting pot of the MHC II peptidome, Curr. Opin. Immunol., 40, 70, 10.1016/j.coi.2016.03.004 · DOI · Paper page
- Sterner, 2000, Acetylation of histones and transcription-related factors, Microbiol. Mol. Biol. Rev., 64, 435, 10.1128/mmbr.64.2.435-459.2000 · DOI · Paper page
- Sun, 2020, Ligand design for specific MHC class I molecules on the cell surface, Biochemistry, 59, 4646, 10.1021/acs.biochem.0c00735 · doi:10.1021/acs.biochem.0c00735
- Suzuki, 2016, The cytoplasmic peptide:N-glycanase (NGLY1) - structure, expression and cellular functions, Gene, 577, 1, 10.1016/j.gene.2015.11.021 · DOI · Paper page
- Thomas, 2021, Altered glycosylation in cancer: A promising target for biomarkers and therapeutics, Biochimica Biophysica Acta - Rev. Cancer, 1875, 188464, 10.1016/j.bbcan.2020.188464 · DOI · Paper page
- Ting, 2018, The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis, J. Biol. Chem., 293, 3236, 10.1074/jbc.ra117.001013 · DOI · Paper page
- Unanue, 2016, Variations in MHC class II antigen processing and presentation in health and disease, Annu. Rev. Immunol., 34, 265, 10.1146/annurev-immunol-041015-055420 · DOI · Paper page
- van Hall, 2012, Mechanisms of peptide vaccination in mouse models: Tolerance, immunity, and hyperreactivity, Adv. Immunol., 114, 51, 10.1016/B978-0-12-396548-6.00003-2 · DOI
- van Hall, 2006, Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants, Nat. Med., 12, 417, 10.1038/nm1381 · DOI · Paper page
- van Stipdonk, 2009, Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100, Cancer Res., 69, 7784, 10.1158/0008-5472.can-09-1724 · DOI · Paper page
- Velloso, 2004, Determination of structural principles underlying three different modes of lymphocytic choriomeningitis virus escape from CTL recognition, J. Immunol., 172, 5504, 10.4049/jimmunol.172.9.5504 · DOI · Paper page
- Vigneron, 2004, An antigenic peptide produced by peptide splicing in the proteasome, Science, 304, 587, 10.1126/science.1095522 · DOI · Paper page
- Vizcaíno, 2020, The human immunopeptidome project: A roadmap to predict and treat immune diseases, Mol. Cell. Proteomics, 19, 31, 10.1074/mcp.r119.001743 · DOI · Paper page
- Warren, 2006, An antigen produced by splicing of noncontiguous peptides in the reverse order, Science, 313, 1444, 10.1126/science.1130660 · DOI · Paper page
- Wolfert, 2013, Adaptive immune activation: Glycosylation does matter, Nat. Chem. Biol., 9, 776, 10.1038/nchembio.1403 · DOI · Paper page
- Wolpert, 1997, Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells, Proc. Natl. Acad. Sci. U. S. A., 94, 11496, 10.1073/pnas.94.21.11496 · DOI
- Wu, 2018, TSNAdb: A database for tumor-specific neoantigens from immunogenomics data analysis, Genomics Proteomics Bioinforma., 16, 276, 10.1016/j.gpb.2018.06.003 · DOI · Paper page
- Yamamoto, 2019, Identification and structure of an MHC class I–encoded protein with the potential to PresentN-myristoylated 4-mer peptides to T cells, J. I., 202, 3349, 10.4049/jimmunol.1900087 · DOI
- Yi, 2021, caAtlas: An immunopeptidome atlas of human cancer, iScience, 24, 103107, 10.1016/j.isci.2021.103107 · DOI · Paper page
- Zarling, 2006, Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy, Proc. Natl. Acad. Sci. U. S. A., 103, 14889, 10.1073/pnas.0604045103 · DOI · Paper page
- Zavala-Cerna, 2014, The clinical significance of posttranslational modification of autoantigens, Clin. Rev. Allergy Immunol., 47, 73, 10.1007/s12016-014-8424-0 · DOI
- Zhang, Metabolic regulation of gene expression by histone lactylation, Nature, 574, 575, 10.1038/s41586-019-1678-1 · DOI · Paper page
- Zhang, Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy, Biomed. Pharmacother., 120, 109542, 10.1016/j.biopha.2019.109542 · DOI · Paper page
Cited by
Kelly, J. J., Bloodworth, N., Shao, Q., Shabanowitz, J., Hunt, D., Meiler, J., & Pires, M. M. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00312 · Cited by 15
PANDORA v2.0: Benchmarking peptide-MHC II models and software improvements
Parizi, F. M., Marzella, D. F., Ramakrishnan, G., ‘t Hoen, P. A. C., Karimi-Jafari, M. H., & Xue, L. C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285899 · Cited by 14
Metadata
- Authors
- Sandalova, T., Sala, B. M., & Achour, A.
- Venue
- Frontiers in Chemistry
- Publisher
- Frontiers Media SA
- Published
- 2022-08-09
- Volume
- 10
- ISSN
- 2296-2646
- Cited by
- 21
- References
- 14
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structural aspects of chemical modifications in the MHC-restricted immunopeptidome; Implications for immune recognition. https://app.cochat.ai/papers/10.3389/fchem.2022.861609
- The paper
- Sandalova, T., Sala, B. M., & Achour, A. (2022). Structural aspects of chemical modifications in the MHC-restricted immunopeptidome; Implications for immune recognition. Frontiers in Chemistry. https://doi.org/10.3389/fchem.2022.861609
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.